News | June 15, 2024
Jubilant Draximage to invest US$ 50 million to expand its PET radiopharmacy network
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Additional data from APPRAISE ATP trial reinforce modular therapy approach
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Subscribe To Our Newsletter & Stay Updated
